Bone Therapeutics SA (BT1.BE)
| Previous Close | 0.0088 |
| Open | 0.0088 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0088 - 0.0093 |
| 52 Week Range | 0.0061 - 0.0820 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Oct 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireBioSenic S.A. : Transparency notification received from ABO Infinium Americas OpCo LTD.
REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, October 7, 2024, 7:00 CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received a transparency notification from ABO Infinium Americas OpCo LTD. The details of the transparency notification are set out below and the full text of the transparen
- GlobeNewswire
BioSenic announces that it has started to look for new assets, the securing of its financing for the coming months by means of an amendment to its convertible bond contract, a change to the composition of its board of directors
PRIVILEGED INFORMATION Biosenic and Global Tech Opportunities 15 ("GTO 15") have entered into an amendment to the convertible bonds ("CB") agreement securing a further EUR 1.5 million of the programme, including at least two tranches of EUR 0.2 million net each.François Rieger and Véronique Pomi-Schneiter resign from their positions as CEO, chairman and executive director and non-executive director respectively, to focus on Medsenic. Finsys Management SRL, represented by its permanent representa
